Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · MetaVia Inc. (MTVA)

MetaVia reports 68% placebo-adjusted liver fat cut in DA-1726 Phase 1 interim data

Positive Impact 4 of 5 product/contract Written later

MetaVia said interim Part 3B data from its Phase 1 trial of DA-1726 showed a 68% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss after 16 weeks, with 15 DA-1726-treated and four placebo participants in the interim analysis. The company said the results support a planned 48-week Phase 2 study in up to 150 patients with MetALD and ALD, targeted to begin in the second half of 2027, but the sample is small and full data are not due until the first quarter of 2027.

Key points

  • Liver fat (MRI-PDFF) fell 68% placebo-adjusted at Day 109 (p<0.001); all five participants with baseline steatosis fell below 5%
  • Body weight fell 13.5% placebo-adjusted (p<0.001); HbA1c fell 0.24 percentage points versus placebo (p=0.006) in participants without diabetes
  • One serious adverse event, severe vomiting, was considered possibly related to treatment; the participant recovered
  • Full Part 3A and 3B data expected in Q1 2027; Phase 2 study targeted to start in 2H 2027

The filing

CompanyMetaVia Inc. (MTVA)
Form8-K, current report
Filed with the SECNov 5, 2026, 9:15 AM ET
Accession number0001104659-26-123110

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.